Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Myeloproliferative Disorders 1

Interventions

Cytarabine 11fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Etoposide 7Filgrastim 6Daunorubicin 6Vorinostat 5Specimen Handling 5Decitabine 5Cyclophosphamide 5Busulfan 5Biopsy 5Methotrexate 4Cyclosporine 4venetoclax 3sargramostim 3decitabine and cedazuridine drug combination 3Liposomes 3Injections 3Idarubicin 3CPX-351 3Azacitidine 3tipifarnib 2romidepsin 2pomalidomide 2laromustine 2fludarabine 2Vincristine 2Tretinoin 2Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Myeloproliferative Disorders × olutasidenib × Clear all
NCT05564390 2026-06-03

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡